PROTEUS: A PROspective Randomised Controlled Trial Evaluating the Use of Artificial Intelligence in Stress Echocardiology
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,338
- 试验地点
- 20
- 主要终点
- Investigate if EchoGo plus standard care is non-inferior to standard care alone for aiding referral to coronary angiogram following stress echocardiogram (SE)
研究概览
简要总结
PROTEUS is a multicentre, two arm, randomised controlled trial of a medical device to assess the impact of the introduction of EchoGo into the standard care pathway for stress echocardiology.
详细描述
Title: A Prospective Randomised Controlled Trial Evaluating the Use of AI in Stress Echocardiography
Trial design: Multi-centre, two-arm, Randomised Controlled Trial of a medical device. Randomised 1:1 to either:
- Standard care (comparator), or
- Standard care plus AI Platform (EchoGo) Trial participants: Adults undergoing clinically indicated stress echocardiogram (SE) to assess inducible ischaemia at participating NHS Trusts.
Having benchmarked the device performance (Upton 2019), and having successfully deployed and tested the required infrastructure, we now propose to prospectively test the software in clinical practice. Based on the existing data for accuracy we would expect use of the EchoGo Platform in the clinical pathway will have a significant benefit reducing inter-reader variability, increasing accuracy and thereby reducing health costs. To formally evaluate the impact of automated AI quantification and accuracy of the decision to make a referral to coronary angiogram, following stress echocardiography, we propose a prospective, multi-centre, randomised controlled trial that compares provision of an AI derived report to a clinician against clinician-only standard of care. This will provide the highest level of evidence of any potential benefit or disadvantages prior to adoption of the software for widespread clinical implementation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Single (Participant)
盲法说明
Following the stress echocardiogram examination, participants will follow the care pathway determined by the clinical team managing their care. If the participant is assigned to the study intervention arm the EchoGo report will inform this decision making process.
In order to minimise bias in any outcome assessment clinicians will be asked not to share the details of the EchoGo report received for participants within the intervention arm with the participant or with colleagues who may undertake future investigations eg: angiography.If a clinician subsequently considers there is a clinical need to know the details of the EchoGo report this can be made available at the discretion of the study team.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide informed consent
- •Male or female, ≥18 years of age at study entry
- •Referred to an NHS Trust for stress echocardiography for investigation of ischaemic heart disease
排除标准
- •More than moderate valvular heart disease
- •Left ventricular outflow tract obstruction defined as a gradient > 30mmHg (fixed or dynamic; supravalvular, valvular or sub-valvular)
- •Significant co-morbidities (e.g. cancer) with an expected life-expectancy of under 12 months in the investigator's opinion
- •Previous coronary artery bypass graft or other cardiac surgery
- •Congenital or inherited myocardial disease
研究组 & 干预措施
Standard Care (comparator)
Patients will receive standard care
Standard Care plus AI platform (EchoGo)
Patients will receive standard care plus their Echocardiogram will be sent to Ultromics for AI assessment. The report from the assessment will be sent to the clinician, and utilised to inform the patients further care.
干预措施: EchoGo (Diagnostic Test)
结局指标
主要结局
Investigate if EchoGo plus standard care is non-inferior to standard care alone for aiding referral to coronary angiogram following stress echocardiogram (SE)
时间窗: 6 months post stress echo
Outcome measure - AUROC for the ability to make an appropriate referral to coronary angiogram at 6 months following stress echocardiogram. Appropriate management will be defined as a composite of * coronary angiography that demonstrates severe coronary disease fulfilling clinical care guidelines for revascularisation or * decision for medical management/reassurance without unanticipated serious adverse cardiac events Outcome data will be collected from participant's medical records at 3 and 6 months.
次要结局
- Establish if clinical management decision making is affected by review of the EchoGo report.(6 month)
- Establish if using the EchoGo platform affects clinician diagnostic confidence.(3 and 6 months post stress echo)
- Establish if clinician diagnostic performance variance reduces with EchoGo use.(3 and 6 month post stress echo)
- Establish if using Ultromics' EchoGo Platform affects the number of subsequent investigations for cardiovascular disease. for cardiovascular disease(3 and 6 months post stress echo)
- Investigate the appropriate clinical management decisions made when using EchoGo plus standard care compared to standard care alone.(6 month post stress echo)
- Establish if using Ultromics' EchoGo Platform affects patient reported coronary artery disease symptoms.(3 and 6 months post stress echo)
- Investigate if EchoGo plus standard care is superior to standard care alone in predicting the risk of severe cardiovascular disease following stress echocardiogram (SE)(6 month post stress echo)
- Assess the health economics impact of implementation and use of Ultromics' EchoGo platform in NHS units(3 and 6 month post stress echo)